Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) – Investment analysts at Lifesci Capital boosted their FY2025 EPS estimates for Dianthus Therapeutics in a research note issued to investors on Wednesday, March 12th. Lifesci Capital analyst R. Katkhuda now anticipates that the company will earn ($2.50) per share for the year, up from their prior estimate of ($2.53). The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share.
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last released its earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $1.33 million during the quarter, compared to analysts’ expectations of $1.40 million.
Check Out Our Latest Research Report on Dianthus Therapeutics
Dianthus Therapeutics Trading Up 0.2 %
Shares of NASDAQ DNTH opened at $21.33 on Friday. Dianthus Therapeutics has a 12-month low of $18.13 and a 12-month high of $33.77. The stock has a market cap of $631.30 million, a PE ratio of -8.53 and a beta of 1.82. The company has a 50-day moving average of $22.61 and a 200 day moving average of $24.92.
Hedge Funds Weigh In On Dianthus Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DNTH. TCG Crossover Management LLC purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter worth about $32,735,000. Braidwell LP grew its stake in Dianthus Therapeutics by 144.4% during the fourth quarter. Braidwell LP now owns 1,206,589 shares of the company’s stock worth $26,304,000 after buying an additional 712,902 shares during the period. Vestal Point Capital LP grew its stake in Dianthus Therapeutics by 172.2% during the fourth quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company’s stock worth $23,435,000 after buying an additional 680,000 shares during the period. State Street Corp grew its stake in Dianthus Therapeutics by 101.4% during the third quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after buying an additional 413,425 shares during the period. Finally, Octagon Capital Advisors LP grew its stake in Dianthus Therapeutics by 20.8% during the fourth quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock worth $46,002,000 after buying an additional 363,500 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Featured Stories
- Five stocks we like better than Dianthus Therapeutics
- Dividend Payout Ratio Calculator
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Why Invest in 5G? How to Invest in 5G Stocks
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.